Evidence map›Paper›PMID 42146188›Full record

ArticleACS omega2026

Anticryptococcal Evaluation of the Allylimine 3H2: Modulation of Virulence Traits and Synergistic Action with Amphotericin B.

Thais Furtado Ferreira Magalhães, Heber Victor Tolomeu, Luíza Braga Ferreira Dos Santos, Cleide Viviane Buzanello, Danielle Letícia Silva, Gabriella Freitas Ferreira, Julliana Ribeiro Alves Dos Santos, Marliete Carvalho da Costa, Vanessa da Silva Dutra de Carvalho, Daniel Assis Santos and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Thais Furtado Ferreira MagalhãesDepartamento de Microbiologia, Universidade Federal de Minas Gerais, Belo Horizonte, MG 31270-901, Brazil.
Heber Victor TolomeuDepartamento de Química, Universidade Federal de Minas Gerais, Belo Horizonte, MG 31270-901, Brazil.
Luíza Braga Ferreira Dos SantosDepartamento de Química, Universidade Federal de Minas Gerais, Belo Horizonte, MG 31270-901, Brazil.
Cleide Viviane BuzanelloDepartamento de Ciências Ambientais e Ciências Aplicadas À Saúde, Universidade Estadual do Oeste do Paraná, Toledo, PR 85919-110, Brazil.
Danielle Letícia SilvaDepartamento de Microbiologia, Universidade Federal de Minas Gerais, Belo Horizonte, MG 31270-901, Brazil.
Gabriella Freitas FerreiraDepartamento de Farmácia, Universidade Federal de Juiz de Fora, Campus Governador Valadares, Governador Valadares, MG 35010-180, Brazil.
Julliana Ribeiro Alves Dos SantosDepartamento de Microbiologia, Universidade Federal de Minas Gerais, Belo Horizonte, MG 31270-901, Brazil.
Marliete Carvalho da CostaPrograma de Pós-graduação em Biociências Aplicada À Saúde, Universidade CEUMA, São Luís, MA 65075-120, Brazil.
Vanessa da Silva Dutra de CarvalhoDepartamento de Microbiologia, Universidade Federal de Minas Gerais, Belo Horizonte, MG 31270-901, Brazil.
Daniel Assis SantosDepartamento de Microbiologia, Universidade Federal de Minas Gerais, Belo Horizonte, MG 31270-901, Brazil.ORCID https://orcid.org/0000-0002-1108-5666
Cleiton Moreira da SilvaDepartamento de Química, Universidade Federal de Minas Gerais, Belo Horizonte, MG 31270-901, Brazil.ORCID https://orcid.org/0000-0001-9913-8971
Maria Aparecida de Resende-StoianoffDepartamento de Microbiologia, Universidade Federal de Minas Gerais, Belo Horizonte, MG 31270-901, Brazil.
Ângelo de FátimaDepartamento de Química, Universidade Federal de Minas Gerais, Belo Horizonte, MG 31270-901, Brazil.ORCID https://orcid.org/0000-0003-2344-5590

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The development of new antifungal scaffolds is critical for expanding therapeutic options against cryptococcosis. Here, we evaluated the allylimine 3H2 as a potential lead compound against

Identifiers

PMID42146188
PMCPMC13177235

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.